Part II: Minimum Quality Threshold in Preclinical Sepsis Studies (MQTiPSS) for Types of Infections and Organ Dysfunction Endpoints.


Journal

Shock (Augusta, Ga.)
ISSN: 1540-0514
Titre abrégé: Shock
Pays: United States
ID NLM: 9421564

Informations de publication

Date de publication:
01 2019
Historique:
pubmed: 15 8 2018
medline: 28 2 2020
entrez: 15 8 2018
Statut: ppublish

Résumé

Although the clinical definitions of sepsis and recommended treatments are regularly updated, a systematic review has not been done for preclinical models. To address this deficit, a Wiggers-Bernard Conference on preclinical sepsis modeling reviewed the 260 most highly cited papers between 2003 and 2012 using sepsis models to create a series of recommendations. This Part II report provides recommendations for the types of infections and documentation of organ injury in preclinical sepsis models. Concerning the types of infections, the review showed that the cecal ligation and puncture model was used for 44% of the studies while 40% injected endotoxin. Recommendation #8 (numbered sequentially from Part I): endotoxin injection should not be considered as a model of sepsis; live bacteria or fungal strains derived from clinical isolates are more appropriate. Recommendation #9: microorganisms should replicate those typically found in human sepsis. Sepsis-3 states that sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection, but the review of the papers showed limited attempts to document organ dysfunction. Recommendation #10: organ dysfunction definitions should be used in preclinical models. Recommendation #11: not all activities in an organ/system need to be abnormal to verify organ dysfunction. Recommendation #12: organ dysfunction should be measured in an objective manner using reproducible scoring systems. Recommendation #13: not all experiments must measure all parameters of organ dysfunction, but investigators should attempt to fully capture as much information as possible. These recommendations are proposed as "best practices" for animal models of sepsis.

Identifiants

pubmed: 30106873
doi: 10.1097/SHK.0000000000001242
pmc: PMC6296883
mid: NIHMS1502278
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

23-32

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM117519
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI112887
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM118097
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM086308
Pays : United States

Références

Virulence. 2015;6(1):93-100
pubmed: 25654604
ILAR J. 2017 Jul 1;58(1):90-105
pubmed: 28444204
Am J Emerg Med. 2016 Sep;34(9):1788-93
pubmed: 27321936
J Immunol. 2006 Aug 1;177(3):1967-74
pubmed: 16849510
Contrib Nephrol. 2013;182:13-29
pubmed: 23689653
Crit Care Med. 2017 Jul;45(7):e703-e710
pubmed: 28437377
Mol Med. 2012 Sep 07;18:930-7
pubmed: 22634723
Trends Microbiol. 2005 Feb;13(2):58-63
pubmed: 15680764
Curr Opin Pulm Med. 2013 May;19(3):305-9
pubmed: 23411577
Shock. 1995 Aug;4(2):89-95
pubmed: 7496903
Am J Physiol Lung Cell Mol Physiol. 2010 Dec;299(6):L843-51
pubmed: 20935232
PLoS One. 2015 Dec 15;10(12):e0144944
pubmed: 26670718
Crit Care Med. 2017 Aug;45(8):e821-e830
pubmed: 28430696
Nat Immunol. 2002 Apr;3(4):354-9
pubmed: 11912497
Am J Respir Cell Mol Biol. 2011 May;44(5):725-38
pubmed: 21531958
Crit Care Med. 2000 Apr;28(4 Suppl):N3-12
pubmed: 10807312
J Leukoc Biol. 2007 Jan;81(1):137-43
pubmed: 17020929
BMC Res Notes. 2014 Apr 12;7:233
pubmed: 24725742
PLoS One. 2015 Dec 21;10(12):e0144710
pubmed: 26690351
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Clin Kidney J. 2013 Feb;6(1):8-14
pubmed: 27818745
Am J Pathol. 2018 Jan;188(1):6-10
pubmed: 28958817
Biomark Insights. 2015 Sep 15;10(Suppl 4):7-17
pubmed: 26417200
J Appl Physiol (1985). 1993 Jan;74(1):423-7
pubmed: 8444723
Clin Chim Acta. 2016 Sep 1;460:203-10
pubmed: 27387712
Intensive Care Med Exp. 2015 Dec;3(1):48
pubmed: 26215812
Crit Care Med. 2007 Oct;35(10):2262-7
pubmed: 17717490
Biomed Pharmacother. 2017 Feb;86:583-589
pubmed: 28024294
Crit Care Med. 2003 Apr;31(4):1250-6
pubmed: 12682500
Chest. 1991 Dec;100(6):1619-36
pubmed: 1959406
Arterioscler Thromb Vasc Biol. 2015 Jun;35(6):1382-92
pubmed: 25857313
N Engl J Med. 2013 Nov 21;369(21):2063
pubmed: 24256390
Crit Care Med. 2005 Sep;33(9):1903-12
pubmed: 16148458
J Infect Dis. 1997 Jul;176(1):151-7
pubmed: 9207361
JAMA. 2013 Mar 20;309(11):1154-62
pubmed: 23512062
Shock. 2005 Dec;24 Suppl 1:52-7
pubmed: 16374373
Nat Rev Immunol. 2017 Jul;17(7):407-420
pubmed: 28436424
N Engl J Med. 2006 Feb 2;354(5):449-61
pubmed: 16452557
Ann Surg. 1973 Aug;178(2):117-22
pubmed: 4723419
J Trauma Acute Care Surg. 2012 Jun;72(6):1491-501
pubmed: 22695412
FEMS Microbiol Lett. 2005 Jan 1;242(1):127-36
pubmed: 15621429
Med Microbiol Immunol. 2015 Jun;204(3):431-7
pubmed: 25788396
J Infect Dis. 2010 Jan 15;201(2):223-32
pubmed: 20001600
J Diabetes Sci Technol. 2014 Jul;8(4):839-44
pubmed: 24876424
BMC Infect Dis. 2015 Oct 13;15:415
pubmed: 26464061
J Leukoc Biol. 2004 Mar;75(3):413-21
pubmed: 14657207
Shock. 2015 Apr;43(4):334-43
pubmed: 25565644
Intensive Care Med. 2007 Jun;33(6):1094-101
pubmed: 17458540
Crit Care Med. 2016 Mar;44(3):e122-30
pubmed: 26901560
Am J Med. 2012 Jul;125(7):670-8
pubmed: 22608986
Intensive Care Med. 2016 Mar;42(3):361-369
pubmed: 26820880
Appl Physiol Nutr Metab. 2016 Jan;41(1):12-9
pubmed: 26624964
Infect Immun. 1996 Nov;64(11):4733-8
pubmed: 8890233
J Immunol. 1997 Feb 1;158(3):1490-7
pubmed: 9013996
Shock. 2017 May;47(5):658-660
pubmed: 28410332
Microbiology. 2006 Oct;152(Pt 10):3075-90
pubmed: 17005987
J Crit Care. 2017 Apr;38:319-323
pubmed: 28107738
Shock. 2002 Jun;17(6):463-7
pubmed: 12069181
Shock. 2015 Sep;44(3):287
pubmed: 26274365
Crit Care Med. 1998 Nov;26(11):1793-800
pubmed: 9824069
Blood. 1997 May 15;89(10):3727-34
pubmed: 9160678
APMIS. 2011 Feb;119(2):155-63
pubmed: 21208283
Shock. 2004 Feb;21(2):121-5
pubmed: 14752284
Chest. 1992 Jun;101(6):1644-55
pubmed: 1303622
J Immunol. 2005 Aug 1;175(3):1498-506
pubmed: 16034087
Shock. 2019 Jan;51(1):4-9
pubmed: 29877959
Crit Care Med. 2017 Feb;45(2):e213-e221
pubmed: 27632670
Crit Care. 2008;12(5):R129
pubmed: 18939991
Curr Protoc Mouse Biol. 2016 Jun 01;6(2):148-168
pubmed: 27248432
Ann Emerg Med. 2006 Nov;48(5):583-90, 590.e1
pubmed: 17052559
Trends Microbiol. 2005 Jan;13(1):34-40
pubmed: 15639630
Crit Care Med. 2008 Aug;36(8):2316-21
pubmed: 18596625
J Trauma Acute Care Surg. 2014 Mar;76(3):582-92, discussion 592-3
pubmed: 24553523
Innate Immun. 2010 Oct;16(5):288-301
pubmed: 19710099
Dis Model Mech. 2013 Jul;6(4):1031-42
pubmed: 23649820
Intensive Care Med. 2017 Jan;43(1):59-68
pubmed: 27837233
J Infect Dis. 2001 Aug 1;184(3):301-7
pubmed: 11443555
N Engl J Med. 1999 Jan 21;340(3):207-14
pubmed: 9895401
Shock. 2000 Feb;13(2):110-6
pubmed: 10670840
Trends Microbiol. 2011 Apr;19(4):198-208
pubmed: 21296575
Crit Care Med. 2016 Jun;44(6):e420-31
pubmed: 26862708
J Immunol. 2010 Jun 15;184(12):6766-72
pubmed: 20483771
Diabetes Care. 2010 Jan;33 Suppl 1:S11-61
pubmed: 20042772
Crit Care Med. 2006 Nov;34(11):2714-8
pubmed: 16943734
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
JAMA. 1993 Dec 22-29;270(24):2957-63
pubmed: 8254858
J Crit Care. 2013 Apr;28(2):116-25
pubmed: 22981530
Psychoneuroendocrinology. 2013 Jul;38(7):1047-57
pubmed: 23146654
Surg Infect (Larchmt). 2016 Aug;17(4):385-93
pubmed: 27305321
Cell Host Microbe. 2016 Mar 9;19(3):375-87
pubmed: 26962946
Crit Care Med. 2013 Jan;41(1):159-70
pubmed: 23222255
PLoS Med. 2012;9(11):e1001338
pubmed: 23152722
Infect Immun. 1984 Jul;45(1):278-80
pubmed: 6376358
N Engl J Med. 1970 Dec 10;283(24):1313-6
pubmed: 5478453
Circulation. 1997 Apr 1;95(7):1783-90
pubmed: 9107164

Auteurs

Claude Libert (C)

Center for Inflammation Research, VIB, Ghent, Belgium.
Ghent University, Ghent, Belgium.

Alfred Ayala (A)

Rhode Island Hospital & Alpert School of Medicine at Brown University, Providence, Rhode Island.

Michael Bauer (M)

Jena University Hospital, Jena, Germany.

Jean-Marc Cavaillon (JM)

Institut Pasteur, Paris, France.

Clifford Deutschman (C)

Feinstein Institute for Medical Research, Northwell Health, Manhasset, New York.

Claes Frostell (C)

Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden.

Sylvia Knapp (S)

Medical University Vienna, Vienna, Austria.

Andrey V Kozlov (AV)

Ludwig Boltzmann Institute for Experimental and Clinical Traumatology in the AUVA Research Center, Vienna, Austria.

Ping Wang (P)

Feinstein Institute for Medical Research, Manhasset, New York.

Marcin F Osuchowski (MF)

Ludwig Boltzmann Institute for Experimental and Clinical Traumatology in the AUVA Research Center, Vienna, Austria.

Daniel G Remick (DG)

Boston University School of Medicine, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH